European radiopharmaceutical startup Artbio secured a $132 million Series B financing to propel its lead prostate cancer alpha radioligand therapeutic into early clinical testing. The funding will also support expansion of its manufacturing capabilities. Led by ex-Novartis executive Emanuele Ostuni, Artbio aims to position itself competitively against established treatments like Pluvicto and build a scalable infrastructure to support upcoming trials and commercialization plans.